COST-EFFECTIVENESS OF UNIVERSAL VERSUS ASSAY-DRIVEN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME PATIENTS

被引：0

作者：

Coleman, C., I ^{[1
]}

Limone, B. L. ^{[2
]}

机构：

[1] Univ Connecticut, Storrs, CT USA

[2] Hartford Hosp, Hartford, CT 06115 USA

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

10.1016/j.jval.2013.03.1472

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

下载

页码：A284 / A284

页数：1

共 50 条

[1] Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
Coleman, Craig I.
Limone, Brendan L.
AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (03): : 355 - 362
[2] COST-EFFECTIVENESS EVALUATION OF GENOTYPE-GUIDED ANTIPLATELET THERAPY VERSUS UNIVERSAL NEW ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
Jiang, M.
You, J.
VALUE IN HEALTH, 2015, 18 (03) : A20 - A20
[3] COST-EFFECTIVENESS OF UNIVERSAL OR GENOTYPE DRIVEN USE OF AVAILABLE DUAL ANTIPLATELET STRATEGIES IN PATIENTS WITH ACUTE CORONARY SYNDROME
Lee, Soyon
Dhamija, Asha
Parsons, Katelyn
King, Matthew
Kaur, Rajbir
Roberts, Matthew
Coleman, Craig
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E483 - E483
[4] Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome
Jiang, Minghuan
You, Joyce H. S.
PHARMACOGENOMICS, 2016, 17 (07) : 701 - 713
[5] Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients Cost-effectiveness analyses for six European perspectives
Coleman, Craig I.
Limone, Brendan L.
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (01) : 103 - 110
[6] COST-EFFECTIVENESS OF UNIVERSAL OR PHENOTYPE-DRIVEN SELECTION OF DUAL ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROME
Coleman, Craig I.
Limone, Brendan
Lee, Soyon
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E6 - E6
[7] Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in Acute Coronary Syndrome Patients: Cost-Effectiveness Analyses from Five European Perspectives
Coleman, Craig I.
Limone, Brendan L.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B52 - B52
[8] Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in Acute Coronary Syndrome Patients: A Cost-Effectiveness Analysis From a United Kingdom Perspective
Coleman, Craig I.
Limone, Brendan L.
CIRCULATION, 2013, 128 (22)
[9] UNIVERSAL CLOPIDOGREL VERSUS CYP2C19-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS
Jiang, M.
You, J.
VALUE IN HEALTH, 2015, 18 (03) : A19 - A19
[10] COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME
Crespin, D. J.
Federspiel, J. J.
Biddle, A. K.
Jonas, D.
Stearns, S. C.
Rossi, J. S.
VALUE IN HEALTH, 2010, 13 (03) : A162 - A162

← 1 2 3 4 5 →